Sulindac sulfide inhibits sarcoendoplasmic reticulum Ca2+ ATPase, induces endoplasmic reticulum stress response, and exerts toxicity in glioma cells: Relevant similarities to and important differences from celecoxib

Journal of Neuroscience Research

Volumn 91, Issue 3, 2013, Pages 393-406

  White, M C ^a   Johnson, G G ^a   Zhang, W ^a   Hobrath, J V ^a   Piazza, G A ^b   Grimaldi, M ^a  

^a SOUTHERN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Ca2+; Gliotoxicity; GRP78; NSAIDs

Indexed keywords

CASPASE 3; CASPASE 4; CELECOXIB; CYCLOPIAZONIC ACID; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SULINDAC SULFIDE;

ARTICLE; BINDING SITE; CALCIUM HOMEOSTASIS; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INHIBITION; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MITOCHONDRION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITORS; GLIOMA; HUMANS; PYRAZOLES; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SULFONAMIDES; SULINDAC;

EID: 84872607629     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23169     Document Type: Article

References (52)

1. Baron JA. 2003. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37: 1-24.
2. 2+-binding sites. Eur J Biochem 269: 3678-3687.
3. 2+ release. FASEB J 16: 1145-1150.
4. Cerchietti LC, Bonomi MR, Navigante AH, Castro MA, Cabalar ME, Roth BM. 2005. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol 71: 73-81.
5. Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schonthal AH. 2009. Cytotoxic effects of celecoxib on Raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res 34: 250-253.
6. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schonthal AH. 2008. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 7: 38.
7. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M. 2009. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10: 501-507.
8. Egger L, Madden DT, Rheme C, Rao RV, Bredesen DE. 2007. Endoplasmic reticulum stress-induced cell death mediated by the proteasome. Cell Death Differ 14: 1172-1180.
9. Ghosh N, Chaki R, Mandal V, Mandal SC. 2010. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62: 233-244.
10. 2+] elevation: a functional rather than a structural ability. J Neurosci Res 84: 1738-1749.
11. Grimaldi M, Favit A, Alkon DL. 1999. cAMP-induced cytoskeleton rearrangement increases calcium transients through the enhancement of capacitative calcium entry. J Biol Chem 274: 33557-33564.
12. 2+ entry in glial cells. J Neurosci 23: 4737-4745.
13. Grossman SA, Olson J, Batchelor T, Peereboom D, Lesser G, Desideri S, Ye X, Hammour T, Supko JG. 2008. Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma. Neuro Oncol 10: 190-198.
14. 2+ wave initiation and inositol trisphosphate signal transduction in oligodendrocyte progenitors. J Neurochem 80: 405-415.
15. Heytler PG. 1979. Uncouplers of oxidative phosphorylation. Methods Enzymol 55: 462-442.
16. Hussain SG, Ramaiah KV. 2007. Reduced eIF2alpha phosphorylation and increased proapoptotic proteins in aging. Biochem Biophys Res Commun 355: 365-370.
17. Jaffe BM. 1974. Prostaglandins and cancer: an update. Prostaglandins 6: 453-461.
18. Jendrossek V, Handrick R, Belka C. 2003. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 17: 1547-1549.
19. Jiang CC, Chen LH, Gillespie S, Wang YF, Kiejda KA, Zhang XD, Hersey P. 2007. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Cancer Res 67: 9750-9761.
20. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 366: 831-837.
21. Johnson GG, White MC, Grimaldi M. 2011. Stressed to death: targeting endoplasmic reticulum stress response induced apoptosis in gliomas. Curr Pharm Des 17: 284-292.
22. Kang YJ, Kim IY, Kim EH, Yoon MJ, Kim SU, Kwon TK, Choi KS. 2011. Paxilline enhances TRAIL-mediated apoptosis of glioma cells via modulation of c-FLIP, survivin and DR5. Exp Mol Med 43: 24-34.
23. Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schonthal AH. 2004. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 3: 55-62.
24. Kardosh A, Wang W, Uddin J, Petasis NA, Hofman FM, Chen TC, Schonthal AH. 2005. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 4: 571-582.
25. Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen TC, Louie SG, Petasis NA, Schonthal AH. 2008. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2, 5-dimethyl-celecoxib. Cancer Res 68: 843-851.
26. Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, Laforme A, Ramakrishna N, Black PM, Drappatz J, Ciampa A, Folkman J, Kieran M, Wen PY. 2008. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neurooncology 10: 300-308.
27. Kim I, Xu W, Reed JC. 2008. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 7: 1013-1030.
28. Koch GL. 1990. The endoplasmic reticulum and calcium storage. Bioessays 12: 527-531.
29. Luo J, Solimini NL, Elledge SJ. 2009. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
30. Moller T. 2002. Calcium signaling in microglial cells. Glia 40: 184-194.
31. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K, Shiosaka S, Hammarback JA, Urano F, Imaizumi K. 2006. Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26: 9220-9231.
32. Oyadomari S, Mori M. 2004. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11: 381-389.
33. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, et al. 1995. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110-3116.
34. Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schonthal AH. 2006. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5: 19.
35. Pyrko P, Kardosh A, Liu YT, Soriano N, Xiong W, Chow RH, Uddin J, Petasis NA, Mircheff AK, Farley RA, Louie SG, Chen TC, Schonthal AH. 2007. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2, 5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Mol Cancer Ther 6: 1262-1275.
36. Rao CV, Reddy BS. 2004. NSAIDs and chemoprevention. Curr Cancer Drug Targets 4: 29-42.
37. Reardon DA, Quinn JA, Vredenburgh J, Rich JN, Gururangan S, Badruddoja M, Herndon JE2nd, Dowell JM, Friedman AH, Friedman HS. 2005. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103: 329-338.
38. Roe MW, Lemasters JJ, Herman B. 1990. Assessment of Fura-2 for measurements of cytosolic free calcium. Cell Calcium 11: 63-73.
39. 2+ signals induced by ATP and thapsigargin in glioma C6 cells. Calcium pools sensitive to inositol 1, 4, 5-trisphosphate and thapsigargin. Neurochem Int 31: 55-64.
40. Schonthal AH. 2006. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 20: E21.
41. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. 2001. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61: 4375-4381.
42. Shrieve DC, Alexander E, 3rd, Black PM, Wen PY, Fine HA, Kooy HM, Loeffler JS. 1999. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 90: 72-77.
43. Tabas I, Ron D. 2011. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190.
44. 2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. J Biol Chem 280: 31059-31067.
45. Thastrup O, Foder B, Scharff O. 1987. The calcium mobilizing tumor promoting agent, thapsigargin elevates the platelet cytoplasmic free calcium concentration to a higher steady state level. A possible mechanism of action for the tumor promotion. Biochem Biophys Res Commun 142: 654-660.
46. 2+-ATPase. Proc Natl Acad Sci U S A 87: 2466-2470.
47. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, Tsuchiya T, Mori M, Mizushima T. 2004. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 11: 1009-1016.
48. Tuettenberg J, Grobholz R, Korn T, Wenz F, Erber R, Vajkoczy P. 2005. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131: 31-40.
49. Wagemakers M, van der Wal GE, Cuberes R, Alvarez I, Andres EM, Buxens J, Vela JM, Moorlag H, Mooij JJ, Molema G. 2009. COX-2 inhibition combined with radiation reduces orthotopic glioma outgrowth by targeting the tumor vasculature. Transl Oncol 2: 1-7.
50. Weiss H, Amberger A, Widschwendter M, Margreiter R, Ofner D, Dietl P. 2001. Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells. Int J Cancer 92: 877-882.
51. Xu C, Bailly-Maitre B, Reed JC. 2005. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115: 2656-2664.
52. Yang H, Park SH, Choi HJ, Moon Y. 2010. The integrated stress response-associated signals modulates intestinal tumor cell growth by NSAID-activated gene 1 (NAG-1/MIC-1/PTGF-beta). Carcinogenesis 31: 703-711.